Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

700 migraine patients tracked to see how well newer drugs really work

NCT ID NCT07159750

Disease control Sponsor: Hospital Universitari Vall d'Hebron Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This observational study will follow 700 people with migraine who are prescribed anti-CGRP drugs (monoclonal antibodies or gepants) for prevention. Over two years, researchers will track changes in monthly headache days, migraine impact, and disability. The goal is to see how these treatments perform in real-world settings, outside of controlled clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Anti-CGRP drugs (monoclonal antibodies: erenumab, galcanezumab, fremanezumab, eptinezumab; gepants: rimegepant, atogepant)
What this could lead to
If successful, this study could provide real-world evidence on how well these migraine preventives work in everyday practice, helping doctors choose the best treatment for each patient.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by patient selection and other factors. It does not test new drugs but observes existing ones, so no new treatment will emerge directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 700 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2024

Expected to finish

Jan 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Episodic and chronic migraine patients.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Migraine diagnosis according to ICHD-III. * Prescription of erenumab, galcanezumab, fremanezumab, eptinezumab, atogepant or rimegepant according to prescriptor criteria and reimbursement criteria according to local regulations. * Signature of informed consent. Exclusion Criteria: * Presence of headache different from migraine. * Active severe psychiatric condition or cognitive impairment which may affect the ability to consent patient's participation in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic migraine headache are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Headache headache disorder migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic migraine headache Episodic migraine Migraine

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    26 sites in 13 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Charité Universitätsmedizin Berlin

    RECRUITING

    Berlin, Germany

  • FLENI

    RECRUITING

    Buenos Aires, Argentina

  • Fundació Sanitària Mollet

    NOT_YET_RECRUITING

    Mollet del Vallès, Barcelona, Spain

  • Fundación Jiménez Díaz

    RECRUITING

    Madrid, Spain

  • Germans Trias i Pujol Hospital

    RECRUITING

    Badalona, Barcelona, Spain

  • Hospital Clínico Universitario Lozano Blesa

    RECRUITING

    Zaragoza, Spain

  • Hospital General Universitario de Albacete

    RECRUITING

    Albacete, Spain

  • Hospital Santa Maria Lisbon

    RECRUITING

    Lisbon, Portugal

  • Hospital Universitari de Bellvitge

    RECRUITING

    L'Hospitalet de Llobregat, Barcelona, Spain

  • Hospital Universitario Gregorio Marañón

    RECRUITING

    Madrid, Spain

  • Hospital de Viladecans

    RECRUITING

    Viladecans, Barcelona, Spain

  • IRCCS San Raffaele

    RECRUITING

    Roma, Italy

  • LMU University Hospital

    RECRUITING

    München, Germany

  • La Paz University Hospital

    RECRUITING

    Madrid, Spain

  • Mersin University

    RECRUITING

    Mersin, Turkey (Türkiye)

  • National Neurological Institute C. Mondino Foundation

    RECRUITING

    Pavia, Italy

  • Neuroclinic Norway

    RECRUITING

    Lillestrøm, Norway

  • Neuromedica

    RECRUITING

    Medellín, Colombia

  • Pontificia Universidad Católica de Chile

    RECRUITING

    Santiago, Chile

  • Special Hospital for Orthopedics and Rehabilitation "Martin Horvat" Rovinj-Rovigno

    RECRUITING

    Rovinj, Croatia

  • Universiti Putra Malaysia

    RECRUITING

    Serdang, Selangor, Malaysia

  • University of L'Aquila

    RECRUITING

    L’Aquila, Italy

  • University of Miami, Miller School of Medicine

    RECRUITING

    Miami, Florida, 33136, United States

  • University of Modena and Reggio Emilia

    RECRUITING

    Modena, Italy

  • Vall d'Hebron University Hospital

    RECRUITING

    Barcelona, Barcelona, 08035, Spain

  • Wrocław Medical University

    RECRUITING

    Wroclaw, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.